Price and states served both move. Read them off the seller's own site before you enroll.How our reviews work →

10rx vs Framework

An in-depth comparison of two leading GLP-1 Providers

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

By Ruth Calder · Enforcement Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
10rx logo

10rx

8.1
★★★★4.1/5

Best for: semaglutide at $99.67/month, 47% under the register median

Visit 10rx
VS
Framework logo

Framework

8.1
★★★★4.1/5

Best for: semaglutide at $100/month, 63% under the register median

Visit Framework

Two GLP-1 Providers chasing the same patients, trading off price, geography and what lands in the box differently. On our scoring, 10rx opens cheaper — $99.67/mo against $100, and they finish level on 8.1. What follows: the prices, what each plan actually covers, the six-dimension score, where each one is weak, and who should pick which.

Pricing

10rx

Injectablecompounded injection
$99.67/mo
semaglutide

Compounded; GLP-1 options as low as under $100/mo

Injectablecompounded injection
$149.67/mo
tirzepatide

Compounded GLP-1 + GIP

Framework

As low as $25/week (~$100/mo)Compounded
$100/mo
semaglutide
As low as $25/week (~$100/mo)Compounded
$100/mo
tirzepatide

What’s included

10rx

Covered by the monthly price

Medication

In the price

Clinician visits

In the price

Shipping

In the price

Lab work

Not stated

Coaching

Not stated

Framework

Covered by the monthly price

Medication

In the price

Clinician visits

Not stated

Shipping

Not stated

Lab work

Not stated

Coaching

In the price

Score breakdown

Both providers are scored on the same six-dimension framework. The gradient bar marks the stronger side on each dimension.

10rx

8.1/10

Overall

Framework

8.1/10

Value25%

9.6A
vs
B
10.0

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

8.0A
vs
B
8.0

Trust & Safety15%

5.5A
vs
B
6.5

Accessibility10%

5.0A
vs
B
5.0

Support10%

7.0A
vs
B
4.5

Features & Coverage

Feature10rxFramework
Starting Price$99.67/mo$100/mo
Features8 features5 features
States AvailableNot disclosedNot disclosed
Compounded✓ Yes
Brand Name
FSA/HSA Accepted
FDA WarningsNoneNone

About 10rx

10rx sets flat monthly rates on compounded GLP-1: semaglutide at $99.67, tirzepatide at $149.67, with NAD+ and sermorelin sold separately for energy and recovery. A free health quiz online reaches a board-certified telehealth doctor, who reads your history before writing anything, and licensed pharmacy partners handle discreet delivery. The company states it reaches every one of the 50 states. What it does not state is its operating company, its pharmacies, or any terms page.

Read our full 10rx review →

About Framework

Cost can go as low as $25/week, which is roughly $100/mo; no membership fee applies. A doctor guides which of the compounded drugs, semaglutide or tirzepatide, a patient takes. The detail that stands out is the pharmacy: Framework names The Pharmacy Hub, which works under the FDA-registered 503B outsourcing pathway instead of the patient-specific 503A route nearly every direct-to-consumer competitor relies on.

Read our full Framework review →

Pros & Cons

10rx

What we like

  • Semaglutide at $99.67 a month, 47% below the $189 median for the same drug and form across this register
  • Tirzepatide at $149.67 a month, 44% below the $267 median for the same drug and form across this register
  • Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
  • The monthly figure covers medication, consult, shipping
  • No FDA warning letter matched this operator when we searched our enforcement register

Watch-outs

  • No state list is on record here, so whether it serves your state cannot be confirmed from this page
  • No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
  • Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality

Framework

What we like

  • Semaglutide at $100 a month, 47% below the $189 median for the same drug and form across this register
  • Tirzepatide at $100 a month, 63% below the $267 median for the same drug and form across this register
  • Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
  • The monthly figure covers medication and coaching
  • No FDA warning letter matched this operator when we searched our enforcement register

Watch-outs

  • No state list is on record here, so whether it serves your state cannot be confirmed from this page
  • No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
  • Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality

Our Verdict

Both 10rx and Framework score equally well overall — the right choice depends on your priorities.

Choose 10rx if…

You want semaglutide at $99.67/month, 47% under the register median and an opening price near $99.67 a month.

Choose Framework if…

You want semaglutide at $100/month, 63% under the register median and an opening price near $100 a month.

Ready to start? Vetted GLP-1 providers

Vetted telehealth providers that prescribe GLP-1 online.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

6.0

SkinnyRx

Starting below a standard dose, with microdose tiers

8.2

YourEra

Semaglutide at $99/month, 63% under the register median

8.8

Gala

Moving between compounded and brand without changing seller

10rx vs Framework: FAQ

Glossary

The words sellers use, defined. Tap any term.

Continue exploring 10rx and Framework head-to-heads in the same category.

Or see the full category ranking.

Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.